P 2021

Thermostable FGF2 Polypeptide, Use Thereof

DVOŘÁK, Petr; Pavel KREJČÍ; Lukáš BÁLEK; Lívia EISELLEOVÁ; Žaneta KONEČNÁ et. al.

Basic information

Original name

Thermostable FGF2 Polypeptide, Use Thereof

Authors

DVOŘÁK, Petr (203 Czech Republic, guarantor, belonging to the institution); Pavel KREJČÍ (203 Czech Republic, belonging to the institution); Lukáš BÁLEK (203 Czech Republic, belonging to the institution); Lívia EISELLEOVÁ (703 Slovakia, belonging to the institution); Žaneta KONEČNÁ (203 Czech Republic, belonging to the institution); Pavel DVOŘÁK (203 Czech Republic, belonging to the institution); David BEDNÁŘ (203 Czech Republic, belonging to the institution); Jan BREZOVSKÝ (203 Czech Republic, belonging to the institution); Eva ŠEBESTOVÁ (203 Czech Republic, belonging to the institution); Radka CHALOUPKOVÁ (203 Czech Republic, belonging to the institution); Veronika ŠTĚPÁNKOVÁ; Pavel VAŇÁČEK; Zbyněk PROKOP; Jiří DAMBORSKÝ (203 Czech Republic, belonging to the institution) and Michaela BOSÁKOVÁ (203 Czech Republic, belonging to the institution)

Edition

Number: SG11201804402W, Publisher: Intellectual Property Office of Singapore (IPOS), Place of publication: Singapur, Owner's name: Masarykova univerzita; Enantis s.r.o. 2021

Other information

Language

English

Type of outcome

Patent

Country of publisher

Singapore

Confidentiality degree

is not subject to a state or trade secret

References:

URL

RIV identification code

RIV/00216224:14310/21:00121632

Organization

Přírodovědecká fakulta – Repository – Repository

Keywords in English

Fibroblast Growth Factor 2; FGF2

Links

LO1214, research and development project.
Changed: 1/6/2022 02:28, RNDr. Daniel Jakubík

Abstract

V originále

The invention provides an isolated thermostable polypeptide possessing FGF2 activity and having at least 85% sequence identity to SEQ ID NO: 2 (FGF2 wt) or a functional fragment thereof, and comprising at least one amino acid substitution R31L and the use thereof in the cell biology research, regenerative medicine and related medical applications or cosmetics. Further it discloses a culture medium comprising subjected FGF2 suitable for culturing a human pluripotent stem cells involving both human embryonic stem cells and induced pluripotent stem cells.
Displayed: 6/7/2025 17:33